Patterns of Interstitial Lung Disease in Egyptian Patients with Systemic Sclerosis: Relation to Disease Parameters

被引:2
|
作者
Abdelati, Abeer Ali [1 ]
Deghady, Akram Abd-Elmonaem [2 ]
Abdelhady, Ahmed Mohamed [3 ]
Bastawy, Rim Aly [4 ]
Shaaban, Ahmed [1 ]
机构
[1] Alexandria Univ, Fac Med, Dept Internal Med, Rheumatol & Clin Immunol Unit, Alexandria, Egypt
[2] Alexandria Univ, Fac Med, Dept Clin & Chem Pathol, Alexandria, Egypt
[3] Alexandria Univ, Fac Med, Chest Dept, Alexandria, Egypt
[4] Alexandria Univ, Fac Med, Dept Radiodiag, Alexandria, Egypt
关键词
Systemic sclerosis; interstitial; HRCT; interleukin-33; pneumonia; pleuroparenchymal fibroelastosis; SCLERODERMA; MANIFESTATIONS; CLASSIFICATION; PNEUMONIA; CYTOKINE; TRIALS; IL-33; CELL;
D O I
10.2174/1573397118666220818095927
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Pulmonary involvement is the most common leading cause of morbidity and mortality associated with systemic sclerosis. Therefore, identifying the various patterns of pulmonary affection is crucial in the clinical management of these patients. In the current study, we aim to investigate the patterns of interstitial lung disease (ILD) associated with SSc patients (SSc-ILD) and their relation to serologic markers and clinical parameters. Methods A cross-sectional study was undertaken on thirty-four adult SSc patients who met the 2013 ACR/EULAR criteria for SSc and Forty healthy controls of matched age and sex. The patients were subjected to history taking, clinical examination, skin assessment using the modified Rodnan Skin Score (mRSS), chest x-ray (CXR), pulmonary function test (PFTs), and high resolution computed tomography of the chest (HRCT). Routine laboratory tests were conducted in addition to immunologic tests and an enzyme-linked immunosorbent assay (ELISA) to determine the IL-33 level. Results ILD was found in 23 SSc patients (67.6%); 20 patients had diffuse type while 3 patients had limited type. Non-specific interstitial pneumonia (NSIP) was found in 56.5%, usual interstitial pneumonia (UIP) was found in 21.7%, pleuroparenchymal fibroelastosis (PPFE) was found in 8.7%, and organizing pneumonia (OP) with the mixed pattern was found in 13% of SSc patients. Additionally, the mean IL-33 level in SSc patients was 98 +/- 12.7 compared to 66.2 +/- 10.6 in the control group (p < 0.001), with ILD patients having a significantly higher level (101.7 +/- 13.4) than those without (90.4 +/- 6.2), and a strong positive correlation with mRSS. Conclusion Even in asymptomatic patients with SSc, ILD is prevalent, with NSIP being the most common pattern. IL-33 could be considered a potential biomarker for predicting the presence of ILD in SSc patients.
引用
收藏
页码:189 / 196
页数:8
相关论文
共 50 条
  • [31] Clinical algorithms for the diagnosis and prognosis of interstitial lung disease in systemic sclerosis
    Hax, Vanessa
    Bredemeier, Markus
    Didonet Moro, Ana Laura
    Pavan, Thais Rohde
    Vieira, Marcelo Vasconcellos
    Pitrez, Eduardo Hennemann
    da Silva Chakr, Rafael Mendonca
    Xavier, Ricardo Machado
    SEMINARS IN ARTHRITIS AND RHEUMATISM, 2017, 47 (02) : 228 - 234
  • [32] Pleuroparenchymal fibroelastosis in systemic sclerosis-associated interstitial lung disease
    Sari, Alper
    Onder, Omer
    Armagan, Berkan
    Bolek, Ertugrul Cagri
    Farisogullari, Bayram
    Bilgin, Emre
    Yardimci, Gozde Kubra
    Ariyurek, Macit
    Akdogan, Ali
    TURKISH JOURNAL OF MEDICAL SCIENCES, 2022, 52 (01) : 83 - 88
  • [33] Systemic sclerosis associated interstitial lung disease
    Xanthouli, P.
    Hermann, W.
    Hunzelmann, N.
    Kreuter, M.
    PNEUMOLOGE, 2018, 15 (06): : 383 - 395
  • [34] Systemic Sclerosis Associated Interstitial Lung Disease
    Steen, Virginia
    Weir, Nargues
    CURRENT RESPIRATORY MEDICINE REVIEWS, 2015, 11 (02) : 110 - 118
  • [35] Interstitial Lung Disease Associated with Systemic Sclerosis
    Mismetti, Valentine
    Si-Mohamed, Salim
    Cottin, Vincent
    SEMINARS IN RESPIRATORY AND CRITICAL CARE MEDICINE, 2024, 45 (03) : 342 - 364
  • [36] Disease staging and sub setting of interstitial lung disease associated with systemic sclerosis: impact on therapy
    George, Peter M.
    Wells, Athol U.
    EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2018, 14 (02) : 127 - 135
  • [37] Effects of nintedanib in patients with limited cutaneous systemic sclerosis and interstitial lung disease
    Allanore, Yannick
    Khanna, Dinesh
    Smith, Vanessa
    Aringer, Martin
    Hoffmann-Vold, Anna-Maria
    Kuwana, MasatakaKuwana
    Merkel, Peter A.
    Stock, Christian
    Sambevsk, Steven
    Denton, Christopher P.
    RHEUMATOLOGY, 2024, 63 (03) : 639 - 647
  • [38] An Analysis of Connective Tissue Disease-associated Interstitial Lung Disease at a US Tertiary Care Center: Better Survival in Patients with Systemic Sclerosis
    Su, Robert
    Bennett, Mihoko
    Jacobs, Susan
    Hunter, Tessa
    Bailey, Carissa
    Krishnan, Eswar
    Rosen, Glenn
    Chung, Lorinda
    JOURNAL OF RHEUMATOLOGY, 2011, 38 (04) : 693 - 701
  • [39] Systemic Sclerosis Associated Interstitial Lung Disease: New Directions in Disease Management
    Mirsaeidi, Mehdi
    Barletta, Pamela
    Glassberg, Marilyn K.
    FRONTIERS IN MEDICINE, 2019, 6
  • [40] Lung Ultrasound as a Screening Method for Interstitial Lung Disease in Patients With Systemic Sclerosis
    Isabel Hassan, Romina
    Lubertino, Lucia, I
    Angeles Barth, Maria
    Fernanda Quaglia, Maria
    Fabiana Montoya, Sandra
    Kerzberg, Eduardo
    del Carmen Binda, Maria
    JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2019, 25 (07) : 304 - 307